

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 28, 2018 (the “Prospectus”) issued by Fusen Pharmaceutical Company Limited (the “Company”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The Company makes this announcement pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong) and this announcement is for information purposes only and does not constitute an offer or an invitation by any person to acquire, purchase or subscribe for securities of the Company.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “U.S. Securities Act”). The securities may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. There will be no public offer of securities in the United States.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(the “Company”)

(Stock code: 1652)

END OF STABILIZATION PERIOD, STABILIZATION ACTIONS AND LAPSE OF OVER-ALLOTMENT OPTION

The Company announces that the stabilization period in connection with the Global Offering ended on Friday, August 3, 2018. No stabilization action was taken by the Stabilizing Manager during the stabilization period. The Over-allotment Option was not exercised by the Joint Global Coordinators (on behalf of the International Underwriters) during the stabilization period and lapsed on Friday, August 3, 2018.

END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on Friday, August 3, 2018, being the 30th day after the date of closing of the application lists under the Hong Kong Public Offering.

STABILIZATION ACTIONS AND LAPSE OF OVER-ALLOTMENT OPTION

As there was no over-allocation of the Shares in the International Offering, the Over-allotment Option was not exercised by the Joint Global Coordinators (on behalf of the International Underwriters) during the stabilization period and no stabilization action was carried out by the Stabilizing Manager in relation to the Global Offering during the stabilization period. The Over-allotment Option lapsed on Friday, August 3, 2018.

PUBLIC FLOAT

The Directors confirm that the Company continues to comply with the public float requirement under Rule 8.08(1) of the Listing Rules whereby at least 25% of the Company's total number of issued shares must at all times be held by the public.

By order of the Board of Directors
Fusen Pharmaceutical Company Limited
Cao Changcheng
Chairman

Hong Kong, August 3, 2018

As at the date of this announcement, the Board of the Company comprises Mr. Cao Changcheng, Mr. Hou Taisheng, Mr. Chi Yongsheng, Ms. Meng Qingfen and Mr. Cao Dudu as the executive Directors; Mr. Wang Jianhang as the non-executive Director; and Mr. Sze Wing Chun, Mr. Shang Lei and Mr. Ho Ka Chun as the independent non-executive Directors.